How much funding has Matchpoint Therapeutics raised?

Matchpoint Therapeutics has raised $100.0M in total funding, most recently a Series A round.

Who are Matchpoint Therapeutics's investors?

Matchpoint Therapeutics's investors include Atlas Venture, Sanofi Ventures, Digitalis Ventures, Alexandria Venture Investments, venBIO Partners, Westlake Village BioPartners.

When was Matchpoint Therapeutics founded?

Matchpoint Therapeutics was founded in 2022.

Where is Matchpoint Therapeutics headquartered?

Matchpoint Therapeutics is headquartered in Boston, Massachusetts, United States.

What industry is Matchpoint Therapeutics in?

Matchpoint Therapeutics operates in Biotech, Healthcare.

How many employees does Matchpoint Therapeutics have?

Matchpoint Therapeutics has 11-50 employees.

Matchpoint Therapeutics

Acing the future of covalent medicines.

Boston, United States · Founded 2022 · $100.0M raised

Biotech

Healthcare

Headquarters: Boston, Massachusetts
Employees: 11–50
Founded: 2022
Business Model: B2B

Website: matchpointtx.com
Total Funding: $100.0M
Last Round: $70.0M Series AOct 2022
Rounds: 2

About

Matchpoint Therapeutics is a biotechnology company discovering precision small molecule medicines that harness covalent bonding chemistry to transform the treatment of immune diseases. Its proprietary ACE (Advanced Covalent Exploration) platform integrates industry-leading chemoproteomics, machine learning, and an evolving covalent compound library to identify novel binding sites and design highly selective, potent drugs. Founded in 2022 and backed by Atlas Venture, the company launched with $100 million in combined seed and Series A financing and has entered a collaborative agreement with Novartis to discover and advance novel covalent medicines. Matchpoint's approach expands the druggable proteome by targeting allosteric, transient, and cryptic binding pockets previously inaccessible to conventional drug discovery methods.

Summary

Matchpoint Therapeutics is a Biotech company based in Boston, United States, founded in 2022. It has raised $100.0M in total across 2 rounds, most recently a $70.0M Series A round in Oct 2022. Investors include Atlas Venture, Sanofi Ventures and Digitalis Ventures.

LinkedIn X (Twitter)